Advertisement

Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence

Published:October 28, 2022DOI:https://doi.org/10.1016/j.hpb.2022.10.010

      Abstract

      Background

      To investigate the changes in transplantability between primary and recurrent Hepatocellular carcinoma (HCC) after hepatic resection (HR) and the risk factors for nontransplantable recurrence (NTR).

      Methods

      Consecutive 3122 patients who received HR for primary HCC between 2001 and 2019 were analyzed for changes in transplantability. Predictors of survival and NTR were evaluated using a competing risk analysis.

      Results

      After a median follow-up of 78.3 months, the 5-year overall survival rate was 82.6%. Also, 58.2% of them developed recurrence after a median of 45.6 months. Recurrence occurred in 1205 and 611 patients with primary transplantable and nontransplantable HCC, respectively, of whom 26.1% and 63.2%, respectively, had NTR. Tumor diameter >3 cm [subdistribution hazard ratios (95% CI), 2.00 (1.62–2.48)], major resection [1.20 (1.00–1.43)], pathological grade >2 [1.28 (1.07–1.52)], microvascular invasion [1.74 (1.45–2.08)], and early recurrence (<1 year) [9.22 (7.83–10.87)] were associated with NTR. The overall transplantable pool increased from 72.3% to 77.5%.

      Conclusion

      Microvascular invasion and early recurrence were risk factors for NTR. Nonetheless, the transplantable pool increased after HR, 41.8% of the patients had no recurrence and may not require liver transplantation. If the patient’s liver function is acceptable, HR should be considered the treatment of choice for HCC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • World Health Organization
        Cancer today: international agency for research on cancer.
        (Available from)
        • Llovet J.M.
        • Kelley R.K.
        • Villanueva A.
        • Singal A.G.
        • Pikarsky E.
        • Roayaie S.
        • et al.
        Hepatocellular carcinoma.
        Nat Rev Dis Prim. 2021; 7: 6
        • Cherqui D.
        • Laurent A.
        • Mocellin N.
        • Tayar C.
        • Luciani A.
        • Van Nhieu J.T.
        • et al.
        Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.
        Ann Surg. 2009; 250: 738-746
        • Sapisochin G.
        • Bruix J.
        Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.
        Nat Rev Gastroenterol Hepatol. 2017; 14: 203-217
        • Omata M.
        • Cheng A.L.
        • Kokudo N.
        • Kudo M.
        • Lee J.M.
        • Jia J.
        • et al.
        Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
        Hepatol Int. 2017; 11: 317-370
        • European Association for the Study of the Liver
        Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2018; 69: 182-236
        • Marrero J.A.
        • Kulik L.M.
        • Sirlin C.B.
        • Zhu A.X.
        • Finn R.S.
        • Abecassis M.M.
        • et al.
        Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.
        Hepatology. 2018; 68: 723-750
        • Mazzaferro V.
        • Regalia E.
        • Doci R.
        • Andreola S.
        • Pulvirenti A.
        • Bozzetti F.
        • et al.
        Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
        N Engl J Med. 1996; 334: 693-699
        • Mazzaferro V.
        • Sposito C.
        • Zhou J.
        • Pinna A.D.
        • De Carlis L.
        • Fan J.
        • et al.
        Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.
        Gastroenterology. 2018; 154: 128-139
        • Gorgen A.
        • Rosales R.
        • Sadler E.
        • Beecroft R.
        • Knox J.
        • Dawson L.A.
        • et al.
        Patterns and predictors of mortality after waitlist dropout of patients with hepatocellular carcinoma awaiting liver transplantation.
        Transplantation. 2019; 103: 2136-2143
        • Toso C.
        • Dupuis-Lozeron E.
        • Majno P.
        • Berney T.
        • Kneteman N.M.
        • Perneger T.
        • et al.
        A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
        Hepatology. 2012; 56: 149-156
        • Geissler E.K.
        • Schlitt H.J.
        Immunosuppression for liver transplantation.
        Gut. 2009; 58: 452-463
        • Thuluvath P.J.
        • Robarts P.
        • Chauhan M.
        Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
        J Hepatol. 2021; 75: 1434-1439
        • Park J.W.
        • Chen M.
        • Colombo M.
        • Roberts L.R.
        • Schwartz M.
        • Chen P.J.
        • et al.
        Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.
        Liver Int. 2015; 35: 2155-2166
        • Poon R.T.
        • Fan S.T.
        • Lo C.M.
        • Liu C.L.
        • Wong J.
        Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.
        Ann Surg. 2002; 235: 373-382
        • Ho M.C.
        • Hasegawa K.
        • Chen X.P.
        • Nagano H.
        • Lee Y.J.
        • Chau G.Y.
        • et al.
        Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific primary liver cancer expert meeting (APPLE 2014).
        Liver Cancer. 2016; 5: 245-256
        • Minagawa M.
        • Mise Y.
        • Omichi K.
        • Ichida H.
        • Mizuno T.
        • Yoshioka R.
        • et al.
        Anatomic resection for hepatocellular carcinoma: prognostic impact assessed from recurrence treatment.
        Ann Surg Oncol. 2022; 29: 913-921
        • Kim J.M.
        • Joh J.W.
        • Yi N.J.
        • Choi G.S.
        • Kim K.
        • Lee K.W.
        • et al.
        Predicting hepatocellular carcinoma recurrence beyond Milan criteria after liver resection for solitary hepatocellular carcinoma.
        J Gastrointest Surg. 2020; 24: 2219-2227
        • Gelli M.
        • Sebagh M.
        • Porcher R.
        • Romanelli E.
        • Vibert E.
        • Sa Cunha A.
        • et al.
        Liver resection for early hepatocellular carcinoma: preoperative predictors of non transplantable recurrence and implications for treatment allocation.
        Ann Surg. 2020; 272: 820-826
        • Zheng J.
        • Chou J.F.
        • Gonen M.
        • Vachharajani N.
        • Chapman W.C.
        • Majella Doyle M.B.
        • et al.
        Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort.
        Ann Surg. 2017; 266: 693-701
        • Tsilimigras D.I.
        • Bagante F.
        • Moris D.
        • Hyer J.M.
        • Sahara K.
        • Paredes A.Z.
        • et al.
        Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria.
        Ann Surg Oncol. 2020; 27: 2321-2331
        • Hwang S.
        • Lee S.G.
        • Moon D.B.
        • Ahn C.S.
        • Kim K.H.
        • Lee Y.J.
        • et al.
        Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma.
        Liver Transplant. 2007; 13: 741-746
        • Belghiti J.
        • Cortes A.
        • Abdalla E.K.
        • Regimbeau J.M.
        • Prakash K.
        • Durand F.
        • et al.
        Resection prior to liver transplantation for hepatocellular carcinoma.
        Ann Surg. 2003; 238 (; discussion 92-3): 885-892
        • Kim B.W.
        • Park Y.K.
        • Kim Y.B.
        • Wang H.J.
        • Kim M.W.
        Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk.
        Transplant Proc. 2008; 40: 3558-3561
        • Ho C.M.
        • Wu C.Y.
        • Lee P.H.
        • Lai H.S.
        • Ho M.C.
        • Wu Y.M.
        • et al.
        Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
        Ann Surg Oncol. 2013; 20: 2526-2533
        • Yao F.Y.
        • Ferrell L.
        • Bass N.M.
        • Watson J.J.
        • Bacchetti P.
        • Venook A.
        • et al.
        Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
        Hepatology. 2001; 33: 1394-1403
        • Ho M.C.
        • Huang G.T.
        • Tsang Y.M.
        • Lee P.H.
        • Chen D.S.
        • Sheu J.C.
        • et al.
        Liver resection improves the survival of patients with multiple hepatocellular carcinomas.
        Ann Surg Oncol. 2009; 16: 848-855
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Hong Y.M.
        • Cho M.
        • Yoon K.T.
        • Chu C.W.
        • Yang K.H.
        • Park Y.M.
        • et al.
        Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma.
        Tumour Biol. 2017; 391010428317720863
        • Ho C.M.
        • Lee C.H.
        • Lee M.C.
        • Zhang J.F.
        • Chen C.H.
        • Wang J.Y.
        • et al.
        Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis.
        Front Oncol. 2020; 10616094
        • Groeschl R.T.
        • Gamblin T.C.
        • Turaga K.K.
        Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint.
        Ann Surg Oncol. 2013; 20: 3591-3595
        • Fine J.P.
        • Gray R.J.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94
        • Tabrizian P.
        • Jibara G.
        • Shrager B.
        • Schwartz M.
        • Roayaie S.
        Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.
        Ann Surg. 2015; 261: 947-955
        • Mehta N.
        • Dodge J.L.
        • Hirose R.
        • Roberts J.P.
        • Yao F.Y.
        Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: implications for organ allocation.
        Am J Transplant. 2019; 19: 2210-2218
        • Lai Q.
        • Sapisochin G.
        • Gorgen A.
        • Vitale A.
        • Halazun K.J.
        • Iesari S.
        • et al.
        Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant.
        JAMA Surg. 2021; 156e213112
        • Di Sandro S.
        • Centonze L.
        • Pinotti E.
        • Lauterio A.
        • De Carlis R.
        • Romano F.
        • et al.
        Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.
        Updates Surg. 2019; 71: 285-293
        • Tsilimigras D.I.
        • Bagante F.
        • Sahara K.
        • Moris D.
        • Hyer J.M.
        • Wu L.
        • et al.
        Prognosis after resection of Barcelona clinic liver cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification.
        Ann Surg Oncol. 2019; 26: 3693-3700
        • Furukawa K.
        • Shiba H.
        • Horiuchi T.
        • Shirai Y.
        • Haruki K.
        • Fujiwara Y.
        • et al.
        Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona clinic liver cancer classification.
        J Hepatobiliary Pancreat Sci. 2017; 24: 199-205
        • Ikegami T.
        • Shimada M.
        • Imura S.
        • Yoshizumi T.
        • Arakawa Y.
        • Tokunaga T.
        • et al.
        The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria.
        Transplantation. 2008; 86: 641-646
        • Kim W.J.
        • Lim T.W.
        • Park P.J.
        • Choi S.B.
        • Kim W.B.
        Prognostic markers affecting the early recurrence of hepatocellular carcinoma with liver cirrhosis after curative resection.
        Int J Biol Markers. 2019; 34: 123-131
        • Erstad D.J.
        • Tanabe K.K.
        Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma.
        Ann Surg Oncol. 2019; 26: 1474-1493
        • Nakagawa S.
        • Yamashita Y.I.
        • Umezaki N.
        • Yamao T.
        • Kaida T.
        • Hiyoshi Y.
        • et al.
        Four gene intrahepatic metastasis-risk signature predicts hepatocellular carcinoma malignant potential and early recurrence from intrahepatic metastasis.
        Surgery. 2021; 169: 903-910
        • Sugimachi K.
        • Maehara S.
        • Tanaka S.
        • Shimada M.
        • Sugimachi K.
        Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma.
        J Hepatobiliary Pancreat Surg. 2001; 8: 410-416
        • Lee S.
        • Hyuck David Kwon C.
        • Man Kim J.
        • Joh J.W.
        • Woon Paik S.
        • Kim B.W.
        • et al.
        Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
        Liver Transplant. 2014; 20: 1057-1063
        • Serenari M.
        • Prosperi E.
        • Allard M.A.
        • Paterno M.
        • Golse N.
        • Laurenzi A.
        • et al.
        The Impact of time interval between hepatic resection and liver transplantation on clinical outcome in patients with hepatocellular carcinoma.
        Cancers. 2021; 13
        • Brown Z.J.
        • Greten T.F.
        • Heinrich B.
        Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy.
        Hepatology. 2019; 70: 1437-1442
        • Rodriguez-Peralvarez M.
        • Luong T.V.
        • Andreana L.
        • Meyer T.
        • Dhillon A.P.
        • Burroughs A.K.
        A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability.
        Ann Surg Oncol. 2013; 20: 325-339
        • Halazun K.J.
        • Najjar M.
        • Abdelmessih R.M.
        • Samstein B.
        • Griesemer A.D.
        • Guarrera J.V.
        • et al.
        Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the Story.
        Ann Surg. 2017; 265: 557-564
        • Wang W.
        • Guo Y.
        • Zhong J.
        • Wang Q.
        • Wang X.
        • Wei H.
        • et al.
        The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma.
        Sci Rep. 2021; 11: 2415
        • Lee S.
        • Kang T.W.
        • Song K.D.
        • Lee M.W.
        • Rhim H.
        • Lim H.K.
        • et al.
        Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation.
        Ann Surg. 2021; 273: 564-571
        • Liu S.C.
        • Lai J.
        • Huang J.Y.
        • Cho C.F.
        • Lee P.H.
        • Lu M.H.
        • et al.
        Predicting microvascular invasion in hepatocellular carcinoma: a deep learning model validated across hospitals.
        Cancer Imag. 2021; 21: 56
        • Poon R.T.
        • Fan S.T.
        • Lo C.M.
        • Liu C.L.
        • Ng I.O.
        • Wong J.
        Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.
        J Clin Oncol. 2000; 18: 1094-1101
        • Yasuda S.
        • Nomi T.
        • Hokuto D.
        • Yoshikawa T.
        • Matsuo Y.
        • Sho M.
        Liver regeneration after major liver resection for hepatocellular carcinoma in the elderly.
        J Invest Surg. 2020; 33: 332-338
        • Dahiya D.
        • Wu T.J.
        • Lee C.F.
        • Chan K.M.
        • Lee W.C.
        • Chen M.F.
        Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience.
        Surgery. 2010; 147: 676-685
        • Vibert E.
        • Schwartz M.
        • Olthoff K.M.
        Advances in resection and transplantation for hepatocellular carcinoma.
        J Hepatol. 2020; 72: 262-276
        • Ruiz E.
        • Fernandez-Placencia R.
        • Bustamante J.
        • Medina-Cana J.
        • Loja E.
        • Berrospi F.
        Monosegment associating liver partition and portal vein ligation for staged hepatectomy: preserving segment 1 as the only liver remnant after hepatocellular carcinoma recurrence.
        Ann Hepatobiliary Pancreat Surg. 2021; 25: 562-565
        • Siriwardana R.C.
        • Lo C.M.
        • Chan S.C.
        • Fan S.T.
        Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study.
        World J Surg. 2012; 36: 1640-1646
        • Ali R.
        • Riaz A.
        • Gabr A.
        • Abouchaleh N.
        • Mora R.
        • Al Asadi A.
        • et al.
        Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
        Eur J Nucl Med Mol Imag. 2017; 44: 2195-2202
        • Hasegawa K.
        • Kokudo N.
        • Imamura H.
        • Matsuyama Y.
        • Aoki T.
        • Minagawa M.
        • et al.
        Prognostic impact of anatomic resection for hepatocellular carcinoma.
        Ann Surg. 2005; 242: 252-259
        • Ahn S.G.
        • Jeon T.J.
        • Lee S.D.
        • Kim S.H.
        • Cho H.J.
        • Yun M.
        • et al.
        A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function.
        Eur J Surg Oncol. 2013; 39: 964-973
        • Ho C.M.
        • Lee P.H.
        • Chen C.L.
        • Ho M.C.
        • Wu Y.M.
        • Hu R.H.
        Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria.
        Ann Surg Oncol. 2012; 19: 826-833
        • Chien R.N.
        • Kao J.H.
        • Peng C.Y.
        • Chen C.H.
        • Liu C.J.
        • Huang Y.H.
        • et al.
        Taiwan consensus statement on the management of chronic hepatitis B.
        J Formos Med Assoc. 2019; 118: 7-38
        • Chang C.H.
        • Lin J.W.
        • Wu L.C.
        • Liu C.H.
        • Lai M.S.
        National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report.
        Med Care. 2013; 51: 908-913
        • Liao S.H.
        • Chen C.L.
        • Hsu C.Y.
        • Chien K.L.
        • Kao J.H.
        • Chen P.J.
        • et al.
        Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan.
        J Hepatol. 2021; 75: 132-141
        • Chiang C.J.
        • Yang Y.W.
        • Chen J.D.
        • You S.L.
        • Yang H.I.
        • Lee M.H.
        • et al.
        Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.
        Hepatology. 2015; 61: 1154-1162
        • Gao X.
        • Yang H.I.
        • Trinh H.
        • Jeong D.
        • Li J.
        • Zhang J.
        • et al.
        Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
        Eur J Gastroenterol Hepatol. 2020; 32: 1207-1211
        • Zhang Y.Q.
        • Guo J.S.
        Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.
        World J Gastroenterol. 2015; 21: 3860-3866
        • Singal A.K.
        • Freeman Jr., D.H.
        • Anand B.S.
        Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.
        Aliment Pharmacol Ther. 2010; 32: 851-858
        • Ikeda K.
        • Kawamura Y.
        • Kobayashi M.
        • Kominami Y.
        • Fujiyama S.
        • Sezaki H.
        • et al.
        Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma.
        Dig Dis Sci. 2017; 62: 2932-2942
        • Wang M.D.
        • Li C.
        • Liang L.
        • Xing H.
        • Sun L.Y.
        • Quan B.
        • et al.
        Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma.
        Oncologist. 2020; 25: e1541-e1551
        • Chiang D.Y.
        • Villanueva A.
        • Hoshida Y.
        • Peix J.
        • Newell P.
        • Minguez B.
        • et al.
        Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
        Cancer Res. 2008; 68: 6779-6788
        • Dominguez D.A.
        • Wang X.W.
        Impact of next-generation sequencing on outcomes in hepatocellular carcinoma: how precise are We really?.
        J Hepatocell Carcinoma. 2020; 7: 33-37
        • Harding J.J.
        • Nandakumar S.
        • Armenia J.
        • Khalil D.N.
        • Albano M.
        • Ly M.
        • et al.
        Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies.
        Clin Cancer Res. 2019; 25: 2116-2126
        • Llovet J.M.
        • Montal R.
        • Sia D.
        • Finn R.S.
        Molecular therapies and precision medicine for hepatocellular carcinoma.
        Nat Rev Clin Oncol. 2018; 15: 599-616
        • Duvoux C.
        • Roudot-Thoraval F.
        • Decaens T.
        • Pessione F.
        • Badran H.
        • Piardi T.
        • et al.
        Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria.
        Gastroenterology. 2012; 143 (e3; quiz e14-5): 986-994